22058 |
Tucatinib |
Tukysa® |
In combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer wo have received at least two prior anti-HER2 treatment regimens. |
Awaiting response from Applicant |
23rd May 2025 |
 |